메뉴 건너뛰기




Volumn 25, Issue 11, 2014, Pages 2244-2251

Corrigenda to Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors [Ann Oncol, 25 (2014) 2244-2251] DOI:10.1093/annonc/mdu390;Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

Author keywords

Breast cancer; FGFR1 amplification; Kinase inhibitor; Lung cancer; Phase I trial

Indexed keywords

FIBROBLAST GROWTH FACTOR; LUCITANIB; TRIACYLGLYCEROL LIPASE; URIC ACID; E-3810; FGFR1 PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; NAPHTHALENE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE; VASCULOTROPIN RECEPTOR 1;

EID: 84925408760     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu547     Document Type: Erratum
Times cited : (153)

References (27)
  • 1
    • 79959713140 scopus 로고    scopus 로고
    • Fibroblast growth factors and their receptors in cancer
    • Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011; 437: 199-213.
    • (2011) Biochem J , vol.437 , pp. 199-213
    • Wesche, J.1    Haglund, K.2    Haugsten, E.M.3
  • 2
    • 84876048479 scopus 로고    scopus 로고
    • Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives
    • Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013; 3: 264-279.
    • (2013) Cancer Discov , vol.3 , pp. 264-279
    • Dieci, M.V.1    Arnedos, M.2    Andre, F.3    Soria, J.C.4
  • 3
    • 80053493427 scopus 로고    scopus 로고
    • Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis
    • Lieu C, Heymach J, Overman M et al. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 2011; 17: 6130-6139.
    • (2011) Clin Cancer Res , vol.17 , pp. 6130-6139
    • Lieu, C.1    Heymach, J.2    Overman, M.3
  • 4
    • 70450175957 scopus 로고    scopus 로고
    • Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
    • Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009; 6: 507-518.
    • (2009) Nat Rev Clin Oncol , vol.6 , pp. 507-518
    • Grothey, A.1    Galanis, E.2
  • 5
    • 0036782278 scopus 로고    scopus 로고
    • VEGF and the quest for tumour angiogenesis factors
    • Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803.
    • (2002) Nat Rev Cancer , vol.2 , pp. 795-803
    • Ferrara, N.1
  • 6
    • 84896691579 scopus 로고    scopus 로고
    • Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
    • Dienstmann R, Rodon J, Prat A et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol 2014; 25: 552-563.
    • (2014) Ann Oncol , vol.25 , pp. 552-563
    • Dienstmann, R.1    Rodon, J.2    Prat, A.3
  • 7
    • 79958112619 scopus 로고    scopus 로고
    • Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer
    • Dutt A, Ramos AH, Hammerman PS et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011; 6: e20351.
    • (2011) PLoS One , vol.6
    • Dutt, A.1    Ramos, A.H.2    Hammerman, P.S.3
  • 8
    • 75149170979 scopus 로고    scopus 로고
    • Fibroblast growth factor signalling: from development to cancer
    • Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 116-129.
    • (2010) Nat Rev Cancer , vol.10 , pp. 116-129
    • Turner, N.1    Grose, R.2
  • 9
    • 59449094654 scopus 로고    scopus 로고
    • Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array
    • Andre F, Job B, Dessen P et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009; 15: 441-451.
    • (2009) Clin Cancer Res , vol.15 , pp. 441-451
    • Andre, F.1    Job, B.2    Dessen, P.3
  • 10
    • 34447325266 scopus 로고    scopus 로고
    • FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
    • Elbauomy ES, Green AR, Lambros MB et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007; 9: R23.
    • (2007) Breast Cancer Res , vol.9
    • Elbauomy, E.S.1    Green, A.R.2    Lambros, M.B.3
  • 11
    • 33845331706 scopus 로고    scopus 로고
    • FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas
    • Reis-Filho JS, Simpson PT, Turner NC et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006; 12: 6652-6662.
    • (2006) Clin Cancer Res , vol.12 , pp. 6652-6662
    • Reis-Filho, J.S.1    Simpson, P.T.2    Turner, N.C.3
  • 12
    • 77950866696 scopus 로고    scopus 로고
    • Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
    • Turner N, Lambros MB, Horlings HM et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29: 2013-2023.
    • (2010) Oncogene , vol.29 , pp. 2013-2023
    • Turner, N.1    Lambros, M.B.2    Horlings, H.M.3
  • 13
    • 84879868244 scopus 로고    scopus 로고
    • FGFR1 and FGF coamplification in breast cancer
    • Albiges L, Albiges L, Quidville V et al. FGFR1 and FGF coamplification in breast cancer. Cancer Res 2009; 69(suppl 3): 4170.
    • (2009) Cancer Res , vol.69 , pp. 4170
    • Albiges, L.1    Albiges, L.2    Quidville, V.3
  • 14
    • 77950278598 scopus 로고    scopus 로고
    • FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer
    • Turner N, Pearson A, Sharpe R et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010; 70: 2085-2094.
    • (2010) Cancer Res , vol.70 , pp. 2085-2094
    • Turner, N.1    Pearson, A.2    Sharpe, R.3
  • 15
    • 79951826312 scopus 로고    scopus 로고
    • E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models
    • Bello E, Colella G, Scarlato V et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res 2011; 71: 1396-1405.
    • (2011) Cancer Res , vol.71 , pp. 1396-1405
    • Bello, E.1    Colella, G.2    Scarlato, V.3
  • 17
    • 0003563862 scopus 로고
    • Study design principles for the clinical evaluation of new drugs as developed by the chemotherapy programme of the National Cancer Institute
    • Staquet MJ (ed). Brussels: Editions Scientifiques Europeenes
    • Carter SK. Study design principles for the clinical evaluation of new drugs as developed by the chemotherapy programme of the National Cancer Institute. In Staquet MJ (ed), The Design of Clinical Trials in Cancer Therapy. Brussels: Editions Scientifiques Europeenes 1973;242-289.
    • (1973) The Design of Clinical Trials in Cancer Therapy , pp. 242-289
    • Carter, S.K.1
  • 19
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    • Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
    • (2009) Eur J Cancer , vol.45 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3
  • 20
    • 80054818768 scopus 로고    scopus 로고
    • Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study
    • Sala F, Bagnati R, Livi V et al. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study. J Mass Spectrom 2011; 46: 1039-1045.
    • (2011) J Mass Spectrom , vol.46 , pp. 1039-1045
    • Sala, F.1    Bagnati, R.2    Livi, V.3
  • 21
    • 84904042903 scopus 로고    scopus 로고
    • Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents-Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
    • Postel-Vinay S, Collette L, Paoletti X et al. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents-Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. Eur J Cancer 2014; 50: 2040-2049.
    • (2014) Eur J Cancer , vol.50 , pp. 2040-2049
    • Postel-Vinay, S.1    Collette, L.2    Paoletti, X.3
  • 22
    • 84893408764 scopus 로고    scopus 로고
    • Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4
    • Gattineni J, Alphonse P, Zhang Q et al. Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4. Am J Physiol Renal Physiol 2014; 306: F351-F358.
    • (2014) Am J Physiol Renal Physiol , vol.306 , pp. F351-F358
    • Gattineni, J.1    Alphonse, P.2    Zhang, Q.3
  • 23
    • 84859415553 scopus 로고    scopus 로고
    • Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer
    • Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012; 18: 1855-1862.
    • (2012) Clin Cancer Res , vol.18 , pp. 1855-1862
    • Brooks, A.N.1    Kilgour, E.2    Smith, P.D.3
  • 24
    • 84910633715 scopus 로고    scopus 로고
    • A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT)
    • Schlumberger M, Tahara M, Wirth L et al. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol 2014; 32(suppl): LBA6008.
    • (2014) J Clin Oncol , vol.32
    • Schlumberger, M.1    Tahara, M.2    Wirth, L.3
  • 25
    • 77951296573 scopus 로고    scopus 로고
    • Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
    • Barrios CH, Liu MC, Lee SC et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010; 121: 121-131.
    • (2010) Breast Cancer Res Treat , vol.121 , pp. 121-131
    • Barrios, C.H.1    Liu, M.C.2    Lee, S.C.3
  • 26
    • 84922981864 scopus 로고    scopus 로고
    • Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR) in patients with advanced solid tumors
    • Andre F, Ranson M, Dean E et al. Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR) in patients with advanced solid tumors. Cancer Res 2013; 73(suppl 1): LB-145.
    • (2013) Cancer Res , vol.73
    • Andre, F.1    Ranson, M.2    Dean, E.3
  • 27
    • 84871527692 scopus 로고    scopus 로고
    • A phase I dose escalation study of NVPBGJ398, a selective pan-FGRR inhibitor in genetically preselected advanced solid tumors
    • Wolf J, LoRusso PM, Camigde RD et al. A phase I dose escalation study of NVPBGJ398, a selective pan-FGRR inhibitor in genetically preselected advanced solid tumors. Cancer Res 2012; 72 (suppl 8): LC-122.
    • (2012) Cancer Res , vol.72
    • Wolf, J.1    LoRusso, P.M.2    Camigde, R.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.